|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy of biological therapies in inflammatory bowel disease:systematic review and meta-analysis显示文摘 | Ford AC Sandborn W J Khan KJ | 2011 | Am J Gastroenterol2011，106，65： | 1 |
| 2 | Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial 显示文摘 | Sandborn W J Schreiber S Feagan B G | 2011 | Clin Gastroenterol Hepatol2011，9，8： | 1 |
| 3 | Infliximab forinduction and maintenance therapy for ulcerative colitis显示文摘 | RUTGEERTS P SANDBORN W J FEAGAN B G | 2005 | NEngl J Med2005，353，23： | 1 |
| 4 | The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review 显示文摘 | SCHOENFELD P SANDBORN W J | 2002 | Aliment Pharmacol Ther2002，16，1： | 1 |
| 5 | Infliximab for induction and maintenance therapy for ulcerative colitis显示文摘 | Rutgeerts P Sandborn W J Feagan B G | | New England Journal of Medicine0，，： | 1 |
| 6 | Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis显示文摘 | Holubar SD Cima RR Sandborn W J | 2010 | Cochrane Database Syst Rev2010，，00： | 1 |
| 7 | Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy显示文摘 | Paul J Limburg David A Ahlquist William J Sandborn Douglas W Mahoney Mary E Devens Jonathan J Harrington Alan R Zinsmeister | 2000 | The American Journal of Gastroenterology2000，，10： | 1 |
| 8 | Crohn's disease in Olmsted County,Minnesota,1940-1993: incidence,prevalence,and survival显示文摘 | SILVERSTEIN M D SANDBORN W J | 1998 | Gastroenterology1998，114，6： | 1 |
| 9 | Biologics in Inflammatory Bowel Disease:How Much Progress have We Made? 显示文摘 | Sandborn W Faubion W | 2004 | Gut2004，53，： | 1 |
| 10 | Management of Crohn's disease in adults显示文摘 | Hanauer SB Sandborn W Practice Parameters Committee of the American College of Gastroenterology | 2001 | Am J Gastroenterol2001，96，3： | 1 |
| 11 | The epidemiology and natural history of crohn's disease in population based patient cohorts from North America: a systematic review显示文摘 | Loftus E V Schoenefld P Sandborn W J | 2002 | Aliment Pharmacol Ther2002，16，1： | 1 |
| 12 | Systematic review:the pharma-cokinetic profiles of oral mesalazine formulations andmesalazine pro-drugs used in the management of ulcerativecolitis显示文摘 | Sandborn W J Hanauer SB | 2003 | Aliment Pharmacol Ther2003，17，1： | 1 |
| 13 | Converging goals of treatment of inflammatory bowel disease from clinical trials and practice显示文摘 | LEVESQUE B G SANDBORN W J Ruel J | 2015 | Gastroenterology2015，148，1： | 1 |
| 14 | Epidemiology of inflammatory bowel disease in Asia显示文摘 | LOFTUS E V SANDBORN W J | 2001 | Inflamm Bowel Dis2001，7，3： | 1 |
| 15 | Diagnosis and treatment of perianal fistulas in crohn' s disease显示文摘 | Schwartz D A Pemberton J H Sandborn W J | 2011 | Ann Inter Med2011，135，10： | 1 |
| 16 | Natalizumab for moder-ate to severe Crohn,s disease in clinical practice: the Mayo ClinicRochester experience显示文摘 | Kane S V Horst S Sandborn W J | 2012 | Inflamm Bowel Dis2012，18，12： | 1 |
| 17 | Infliximab, azathioprine, or combination therapy for Crohn's disease 显示文摘 | Colombel JF Sandborn WJ Reinisch W | 2010 | N Engl J Med2010，362，15： | 1 |
| 18 | CDP571,a Humanised Monoclonal Antibody to Tumournecrosis Factor,for Moderate to Severe Crohn's Disease:a Randomised,double Blind,Placebo Controlled Trial显示文摘 | Sandborn W Feagan G | 2004 | Gut2004，53，： | 1 |
| 19 | Review article : treat- ment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease显示文摘 | Panaccione R Rutgeerts P Sandborn W J | 2008 | Aliment Pharmacol Ther2008，28，： | 1 |
| 20 | Etanereept for active Crohn's disease: a randomized, double-blind, placebo-con- trolled trial 显示文摘 | Sandborn W J Hanauer SB Katz S | 2001 | Gastroenterology2001，121，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员